US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CytoDyn Inc.

0.2490

+0.00301.22%

Volume:1.42M

Turnover:350.90K

Market Cap:312.16M

PE:-7.68

High:0.2550

Open:0.2500

Low:0.2430

Close:0.2460

52wk High:0.4945

52wk Low:0.1911

Shares:1.25B

Float Shares:1.25B

Volume Ratio:1.10

T/O Rate:0.11%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0324

EPS(LYR):-0.2868

ROE:1659.17%

ROA:-70.67%

PB:-2.61

PE(LYR):-0.87

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

CytoDyn announces benefactor committed funding to support EAP

Cytodyn Announces Funding and Initiation of Expanded Access Program for Patients With Triple-Negative Breast Cancer

THOMSON REUTERS

CytoDyn Inc. reports Q2 net loss of USD 22.6 million, widening nearly 5 times

CytoDyn Reports Leronlimab Boosts PD-L1 and Extends Survival in Metastatic Triple-Negative Breast Cancer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CYDY"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"CYDY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CYDY\",,,,,undefined,":{"symbol":"CYDY","market":"US","secType":"STK","nameCN":"CytoDyn Inc.","latestPrice":0.249,"timestamp":1770411600000,"preClose":0.246,"halted":0,"volume":1415209,"delay":15,"changeRate":0.012195121951219523,"floatShares":1252865057,"shares":1253645452,"eps":-0.032401,"marketStatus":"Market Closed","change":0.003,"latestTime":"02-06 16:00:00 EST Delay","open":0.25,"high":0.255,"low":0.243,"amount":350904.9679500001,"amplitude":0.04878,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.032401,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":0.246,"volumeRatio":1.0987333590175592},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CYDY\",,,,,undefined,":{"symbol":"CYDY","floatShares":1252865057,"roa":"-70.67%","roe":"1659.17%","lyrEps":-0.286757,"volumeRatio":1.0987333590175592,"shares":1253645452,"dividePrice":0,"high":0.255,"amplitude":0.04878,"preClose":0.246,"low":0.243,"week52Low":0.1911,"pbRate":"-2.61","week52High":0.4945,"institutionHeld":0,"latestPrice":0.249,"eps":-0.032401,"divideRate":0,"volume":1415209,"delay":15,"ttmEps":-0.032401,"open":0.25,"prevYearClose":0.28,"prevWeekClose":0.2444,"prevMonthClose":0.2444,"prevQuarterClose":0.28,"fiveDayClose":0.2444,"twentyDayClose":0.2779,"sixtyDayClose":0.2495},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CYDY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-01-14","symbol":"CYDY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1736830800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-10-15","symbol":"CYDY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1728964800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-08-15","symbol":"CYDY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723694400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-04-15","symbol":"CYDY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1713153600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-01-16","symbol":"CYDY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1705381200000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CYDY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CYDY\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CYDY\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2606787363","title":"CytoDyn announces benefactor committed funding to support EAP","url":"https://stock-news.laohu8.com/highlight/detail?id=2606787363","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606787363?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:40","pubTimestamp":1769521219,"startTime":"0","endTime":"0","summary":"CytoDyn (CYDY) announced that a benefactor has formally committed funding to support the Company’s Expanded Access Program, EAP, for patients with ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cytodyn-announces-benefactor-committed-funding-to-support-eap-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cytodyn-announces-benefactor-committed-funding-to-support-eap-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CYDY","BK4139"],"gpt_icon":0},{"id":"2606782120","title":"Cytodyn Announces Funding and Initiation of Expanded Access Program for Patients With Triple-Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2606782120","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606782120?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:30","pubTimestamp":1769520602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nTUABCMRNN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CYDY"],"gpt_icon":0},{"id":"2602379881","title":"CytoDyn Inc. reports Q2 net loss of USD 22.6 million, widening nearly 5 times","url":"https://stock-news.laohu8.com/highlight/detail?id=2602379881","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602379881?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:31","pubTimestamp":1767965496,"startTime":"0","endTime":"0","summary":"CytoDyn Inc. reported a net loss of USD 22.6 million for the quarter ending November 30, 2025. Total interest and other expenses for the quarter amounted to USD 919 thousand. No income tax benefit was recognized during the period. Loss per share data was not disclosed in the provided information.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 09, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL4HswCQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CYDY"],"gpt_icon":0},{"id":"2589355624","title":"CytoDyn Reports Leronlimab Boosts PD-L1 and Extends Survival in Metastatic Triple-Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2589355624","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589355624?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:30","pubTimestamp":1765200658,"startTime":"0","endTime":"0","summary":"CytoDyn Inc., a clinical-stage oncology company, announced updated results from a retrospective follow-up analysis involving 28 women with metastatic triple-negative breast cancer  who participated in three leronlimab clinical trials. The findings, which will be presented as a poster at the San Antonio Breast Cancer Symposium on December 12, 2025, indicate that leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells. Among patients who demonstrated significant PD-L1 induction and subsequently received immune checkpoint inhibitors, all remain alive after a median of 60.9 months, with three showing no evidence of disease. No dose-limiting toxicities were observed, and no patients withdrew due to treatment-related adverse events. A copy of the presentation will be made available on CytoDyn's website after the symposium.Disclaimer: This news brief was created by Public Technologies  using generative artificial int","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL7VrqfZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112","SG9999014039.USD","SG9999014013.SGD","BK4588","LU2210150020.SGD","LU2095319765.USD","BK4139","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014005.SGD","NDAQ","LU2210149790.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","CYDY"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CYDY\",params:#limit:6,delay:false,,,undefined,":[]}}